News|Videos|May 5, 2026

8 Endocrinology Headlines You Missed in April 2026

Catch up on key clinician insights, major FDA decisions, groundbreaking trial results, and more.

April was a packed month for endocrinology, with several decisions by the US Food and Drug Administration (FDA) and multiple major trial results reported. Additionally, the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas, Nevada, capped off the month with a series of key clinician insights on everything from GLP-1s in type 1 diabetes (T1D) to the effects of excess iodine on the thyroid.

Related to this article

September 18th, 2026

Diabetes Dialogue: Finerenone Approved for CKD in Type 1 Diabetes

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.

September 17th, 2026

FDA Approves Finerenone (Kerendia) for CKD and Type 1 Diabetes

The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.

September 15th, 2026

Diabetes Dialogue: Beta Bionics' Mint Patch Pump Gains FDA Clearance

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.

Image Credit: US Food and Drug Administration

September 14th, 2026

FDA Clears Beta Bionics' Mint Insulin Patch Pump for Diabetes

Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.

September 10th, 2026

Diabetes Dialogue: Tirzepatide's New CV Indication and the STAREE Statin Trial

Diana Isaacs, PharmD, and Natalie Bellini, DNP, unpack tirzepatide's new CV indication and the STAREE statin trial in older adults.

September 18th, 2026

Dersimelagon Gains FDA Priority Review for EPP, XLP

The FDA has granted Priority Review to dersimelagon for EPP and XLP, setting a PDUFA date for late February 2027 as LEO Pharma completes its acquisition from Tanabe Pharma.